{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T12:19:21Z","timestamp":1791893961651,"version":"4.3.4"},"reference-count":41,"publisher":"Public Library of Science (PLoS)","issue":"1","license":[{"start":{"date-parts":[[2012,1,26]],"date-time":"2012-01-26T00:00:00Z","timestamp":1327536000000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/publicdomain\/zero\/1.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0029900","type":"journal-article","created":{"date-parts":[[2012,1,26]],"date-time":"2012-01-26T16:51:00Z","timestamp":1327596660000},"page":"e29900","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":59,"title":["Effects of a Selective Cannabinoid CB2 Agonist and Antagonist on Intravenous Nicotine Self Administration and Reinstatement of Nicotine Seeking"],"prefix":"10.1371","volume":"7","author":[{"given":"Islam","family":"Gamaleddin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Zvonok","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandros","family":"Makriyannis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven R.","family":"Goldberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernard","family":"Le Foll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2012,1,26]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1503\/cmaj.070627","article-title":"Treatment of tobacco dependence: integrating recent progress into practice.","volume":"177","author":"B Le Foll","year":"2007","journal-title":"CMAJ"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1038\/nrd1495","article-title":"The endocannabinoid system and its therapeutic exploitation.","volume":"3","author":"V Di Marzo","year":"2004","journal-title":"Nat Rev Drug Discov"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1124\/pr.54.2.161","article-title":"International Union of Pharmacology. XXVII. Classification of cannabinoid receptors.","volume":"54","author":"AC Howlett","year":"2002","journal-title":"Pharmacol Rev"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1038\/sj.bjp.0705666","article-title":"The endocannabinoid system: a general view and latest additions.","volume":"141","author":"L De Petrocellis","year":"2004","journal-title":"Br J Pharmacol"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1124\/jpet.109.152710","article-title":"CB1 receptor-independent actions of SR141716 on G-protein signaling: coapplication with the mu-opioid agonist Tyr-D-Ala-Gly-(NMe)Phe-Gly-ol unmasks novel, pertussis toxin-insensitive opioid signaling in mu-opioid receptor-Chinese hamster ovary cells.","volume":"330","author":"R Cinar","year":"2009","journal-title":"J Pharmacol Exp Ther"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1152\/physrev.00004.2003","article-title":"Role of endogenous cannabinoids in synaptic signaling.","volume":"83","author":"TF Freund","year":"2003","journal-title":"Physiol Rev"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1189\/jlb.0303101","article-title":"The cannabinoid system and immune modulation.","volume":"74","author":"TW Klein","year":"2003","journal-title":"J Leukoc Biol"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.molbrainres.2004.08.025","article-title":"Human brain endothelium: coexpression and function of vanilloid and endocannabinoid receptors.","volume":"132","author":"SA Golech","year":"2004","journal-title":"Brain Res Mol Brain Res"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"10529","DOI":"10.1073\/pnas.1834309100","article-title":"Activation of CB2 cannabinoid receptors by AM1241 inhibits experimental neuropathic pain: pain inhibition by receptors not present in the CNS.","volume":"100","author":"MM Ibrahim","year":"2003","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1002\/syn.20050","article-title":"Cannabinoid CB2 receptors are expressed by perivascular microglial cells in the human brain: an immunohistochemical study.","volume":"53","author":"E Nunez","year":"2004","journal-title":"Synapse"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"2530","DOI":"10.1523\/JNEUROSCI.3923-04.2005","article-title":"A glial endogenous cannabinoid system is upregulated in the brains of macaques with simian immunodeficiency virus-induced encephalitis.","volume":"25","author":"C Benito","year":"2005","journal-title":"J Neurosci"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1126\/science.1115740","article-title":"Identification and functional characterization of brainstem cannabinoid CB2 receptors.","volume":"310","author":"MD Van Sickle","year":"2005","journal-title":"Science"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1038\/sj.tpj.6500431","article-title":"Involvement of cannabinoid CB2 receptor in alcohol preference in mice and alcoholism in humans.","volume":"7","author":"H Ishiguro","year":"2007","journal-title":"Pharmacogenomics J"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1016\/j.biopsych.2009.09.024","article-title":"Brain cannabinoid CB2 receptor in schizophrenia.","volume":"67","author":"H Ishiguro","year":"2010","journal-title":"Biol Psychiatry"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1038\/nn.2874","article-title":"Brain cannabinoid CB receptors modulate cocaine&apos;s actions in mice.","volume":"14","author":"ZX Xi","year":"2011","journal-title":"Nat Neurosci"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.1097\/00001756-200409150-00028","article-title":"Rimonabant, a CB<sub>1<\/sub> antagonist, blocks nicotine-conditioned place preferences.","volume":"15","author":"B Le Foll","year":"2004","journal-title":"Neuroreport"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1007\/s00213-005-0015-6","article-title":"Cannabinoid CB1 receptors are involved in motivational effects of nicotine in rats.","volume":"181","author":"B Forget","year":"2005","journal-title":"Psychopharmacology (Berl)"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1097\/00008877-200209000-00018","article-title":"SR141716, a central cannabinoid (CB(1)) receptor antagonist, blocks the motivational and dopamine-releasing effects of nicotine in rats.","volume":"13","author":"C Cohen","year":"2002","journal-title":"Behav Pharmacol"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.pbb.2005.01.024","article-title":"CB1 receptor antagonists for the treatment of nicotine addiction.","volume":"81","author":"C Cohen","year":"2005","journal-title":"Pharmacol Biochem Behav"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/j.neuropharm.2007.10.011","article-title":"The cannabinoid antagonist AM251 attenuates nicotine self-admininstration and nicotine-seeking behaviour in rats.","volume":"52","author":"M Shoaib","year":"2008","journal-title":"Neuropharmacology"},{"key":"ref21","article-title":"Cannabinoid receptor stimulation increases motivation for nicotine and nicotine seeking.","author":"I Gamaleddin","year":"2011"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1007\/BF00589894","article-title":"Nicotine maintains robust self-administration in rats on a limited-access schedule.","volume":"99","author":"WA Corrigall","year":"1989","journal-title":"Psychopharmacology (Berl)"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1007\/s00213-009-1569-5","article-title":"Inhibition of fatty acid amide hydrolase reduces reinstatement of nicotine seeking but not break point for nicotine self-administration\u2013comparison with CB(1) receptor blockade.","volume":"205","author":"B Forget","year":"2009","journal-title":"Psychopharmacology (Berl)"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1017\/S1461145709991064","article-title":"The selective dopamine D3 receptor antagonist SB 277011-A, but not the partial agonist BP 897, blocks cue-induced reinstatement of nicotine-seeking.","volume":"13","author":"MA Khaled","year":"2010","journal-title":"Int J Neuropsychopharmacol"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/BF02245526","article-title":"Heroin self-administration in rats under a progressive ratio schedule of reinforcement.","volume":"111","author":"DC Roberts","year":"1993","journal-title":"Psychopharmacology (Berl)"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.biopsych.2010.01.029","article-title":"Granular insular cortex inactivation as a novel therapeutic strategy for nicotine addiction.","volume":"68","author":"B Forget","year":"2010","journal-title":"Biol Psychiatry"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1038\/npp.2010.62","article-title":"Noradrenergic alpha1 receptors as a novel target for the treatment of nicotine addiction.","volume":"35","author":"B Forget","year":"2010","journal-title":"Neuropsychopharmacology"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/S0009-3084(02)00155-X","article-title":"Inhibition of pain responses by activation of CB(2) cannabinoid receptors.","volume":"121","author":"TP Malan Jr","year":"2002","journal-title":"Chem Phys Lipids"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"3093","DOI":"10.1073\/pnas.0409888102","article-title":"CB2 cannabinoid receptor activation produces antinociception by stimulating peripheral release of endogenous opioids.","volume":"102","author":"MM Ibrahim","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1038\/sj.bjp.0707333","article-title":"Activation of cannabinoid CB1 and CB2 receptors suppresses neuropathic nociception evoked by the chemotherapeutic agent vincristine in rats.","volume":"152","author":"EJ Rahn","year":"2007","journal-title":"Br J Pharmacol"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1097\/FBP.0b013e3283474a6d","article-title":"CB1 and CB2 receptor agonists promote analgesia through synergy in a murine model of tumor pain.","volume":"22","author":"IA Khasabova","year":"2011","journal-title":"Behav Pharmacol"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.ejphar.2008.01.010","article-title":"Involvement of central cannabinoid CB2 receptor in reducing mechanical allodynia in a mouse model of neuropathic pain.","volume":"583","author":"W Yamamoto","year":"2008","journal-title":"Eur J Pharmacol"},{"key":"ref33","article-title":"The MAGL inhibitor, JZL184, attenuates LiCl-induced vomiting in the Suncus murinus and 2AG attenuates LiCl-induced nausea-like behavior in rats.","author":"MA Sticht","year":"2011","journal-title":"Br J Pharmacol"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1111\/j.1476-5381.2010.00819.x","article-title":"Depression-resistant endophenotype in mice overexpressing cannabinoid CB(2) receptors.","volume":"160","author":"MS Garcia-Gutierrez","year":"2010","journal-title":"Br J Pharmacol"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejphar.2004.09.058","article-title":"Species comparison and pharmacological characterization of rat and human CB2 cannabinoid receptors.","volume":"505","author":"S Mukherjee","year":"2004","journal-title":"Eur J Pharmacol"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"e1640","DOI":"10.1371\/journal.pone.0001640","article-title":"Brain neuronal CB2 cannabinoid receptors in drug abuse and depression: from mice to human subjects.","volume":"3","author":"ES Onaivi","year":"2008","journal-title":"PLoS ONE"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1016\/j.neuropharm.2004.12.008","article-title":"Pharmacological and pharmacokinetic characterization of the cannabinoid receptor 2 agonist, GW405833, utilizing rodent models of acute and chronic pain, anxiety, ataxia and catalepsy.","volume":"48","author":"KJ Valenzano","year":"2005","journal-title":"Neuropharmacology"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1016\/j.neuropharm.2007.09.007","article-title":"Effects of the CRF receptor antagonist D-Phe CRF(12\u201341) and the alpha2-adrenergic receptor agonist clonidine on stress-induced reinstatement of nicotine-seeking behavior in rats.","volume":"53","author":"G Zislis","year":"2007","journal-title":"Neuropharmacology"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1124\/jpet.108.142224","article-title":"Inhibition of anandamide hydrolysis by cyclohexyl carbamic acid 3\u2032-carbamoyl-3-yl ester (URB597) reverses abuse-related behavioral and neurochemical effects of nicotine in rats.","volume":"327","author":"M Scherma","year":"2008","journal-title":"J Pharmacol Exp Ther"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1111\/j.1476-5381.2011.01440.x","article-title":"The selective anandamide transport inhibitor VDM11 attenuates reinstatement of nicotine seeking induced by nicotine associated cues and nicotine priming, but does not affect nicotine-intake.","volume":"164","author":"I Gamaleddin","year":"2011","journal-title":"Br J Pharmacol"},{"key":"ref41","article-title":"The anandamide transport inhibitor AM404 reduces the rewarding effects of nicotine and nicotine-induced dopamine elevations in the nucleus accumbens shell in rats.","author":"M Scherma","year":"2011","journal-title":"Br J Pharmacol"}],"container-title":["PLoS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0029900","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,10,24]],"date-time":"2018-10-24T02:18:22Z","timestamp":1540347502000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0029900"}},"subtitle":[],"editor":[{"given":"Xiang Yang","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2012,1,26]]},"references-count":41,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2012,1,26]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0029900","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.14267178.15779352","asserted-by":"object"}]},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,1,26]]}}}